New Skin Sterol data to be presented at American College of Cardiology Annual Conference

New Skin Sterol data to be presented at American College of
Cardiology Annual Conference 


TORONTO, Dec. 9  /PRNewswire-FirstCall/ -- Predictive medicine company IMI
International Medical Innovations Inc. (Amex: IME; TSX: IMI) today announced
that a scientific abstract featuring the company's predictive, non-invasive
test for cardiovascular disease risk assessment, PREVU(x) Skin Sterol Test, has
been accepted for a podium presentation at the 54th Annual Scientific Session
of the American College of Cardiology, to be held in Orlando, Florida from
March 6 - 9, 2005.

"IMI, along with its partner, McNeil Consumer Healthcare, is committed to
positioning PREVU(x) as a leading tool to assess patients' risk of heart
disease," said Dr. Brent Norton, IMI President and CEO. "The relationship
between skin sterol and coronary artery disease has already been proven. We
believe this new data will help foster additional awareness and discussion of
the value of our test among world-leading cardiologists and clinicians."

The abstract accepted for presentation is Skin Cholesterol Content Identifies
Subclinical Atherosclerosis in Asymptomatic Adults, co-authored by Wendy S.
Tzou, Maureen E. Mays, Claudia E. Korcarz, Susan E. Aeschlimann and James H.
Stein, University of Wisconsin Medical School, Madison, Wisconsin.

McNeil Consumer Healthcare will also be exhibiting PREVU(x) Skin Sterol Test at
this important, high profile event.

The American College of Cardiology is dedicated to fostering optimal
cardiovascular care and disease prevention through professional education,
promotion of research, leadership in the development of standards and
guidelines, and the formulation of health care policy. The annual conference,
which attracts about 27,000 delegates and is a premier forum for cardiologists
worldwide, features a unique combination of cutting edge science and practical
clinical applications.

About IMI

IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases. IMI's
cardiovascular products, branded as PREVU(x) Skin Sterol Test, will be marketed
and distributed worldwide by McNeil Consumer Healthcare. The company's cancer
tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. IMI's
head office is located in Toronto, and its research and product development
facility is at McMaster University in Hamilton, Ontario. For further
information, please visit http://www.imimedical.com/.

This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause IMI's
actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the lack of
operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, the
successful development or marketing of IMI's products, reliance on third-party
manufacturers, the competitiveness of IMI's products if successfully
commercialized, the ability of IMI to take advantage of business opportunities,
uncertainties related to the regulatory process, and general changes in
economic conditions. In addition, while IMI routinely obtains patents for its
products and technology, the protection offered by the Company's patents and
patent applications may be challenged, invalidated or circumvented by our
competitors and there can be no guarantee of our ability to obtain or maintain
patent protection for our products or product candidates. Investors should
consult IMI's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned not to rely
on these forward-looking statements. IMI is providing this information as of
the date of this press release and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Company Contact: Sarah Borg-Olivier, Director, Communications,

[phone], ; U.S. Investor Contact, Jane

Lin/Andrea Faville, The Investor Relations Group, [phone],

, 

Copyright